Allan S Jaffe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7747364/publications.pdf

Version: 2024-02-01

333 papers	43,555 citations	6250 80 h-index	2178 202 g-index
340 all docs	340 docs citations	340 times ranked	30810 citing authors

#	Article	IF	Citations
1	Cardiogenic shock complicating non-ST-segment elevation myocardial infarction: An 18-year study. American Heart Journal, 2022, 244, 54-65.	1.2	8
2	High-Sensitivity Troponin T Testing for Pediatric Patients in the Emergency Department. Pediatric Cardiology, 2022, 43, 350-359.	0.6	2
3	The Biological Variability of Plasma Ceramides in Healthy Subjects. journal of applied laboratory medicine, The, 2022, 7, 863-870.	0.6	1
4	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)â€Free Lowâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2022, 11, e023136.	1.6	8
5	Sex disparities in management and outcomes of cardiac arrest complicating acute myocardial infarction in the United States. Resuscitation, 2022, 172, 92-100.	1.3	11
6	Use and Prognostic Implications of Cardiac Troponin in COVID-19. Cardiology Clinics, 2022, 40, 287-300.	0.9	6
7	Revisiting the definition of perioperative myocardial infarction after coronary artery bypass grafting. European Heart Journal, 2022, , .	1.0	4
8	Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Uninsured Compared With Privately Insured Individuals. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008991.	1.6	4
9	Type 1, Type 2 Myocardial Infarction and Non-Ischemic Myocardial Injuryâ€"Opinion from the Front Lines. American Journal of Medicine, 2022, 135, 935-938.	0.6	2
10	Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction. Journal of the American Heart Association, 2022, 11, e022852.	1.6	15
11	Professor Giora Landesberg, MD, DSc, MBA, 1954-2021: A Physician and Research Pioneer in Perioperative Myocardial Infarction. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 1254-1257.	0.6	0
12	Rapid Exclusion of Acute Myocardial Injury and Infarction With a Single High-Sensitivity Cardiac Troponin T in the Emergency Department: A Multicenter United States Evaluation. Circulation, 2022, 145, 1708-1719.	1.6	15
13	Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays: Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers. Clinical Chemistry, 2022, 68, 1022-1030.	1.5	26
14	Major adverse cardiovascular events after diagnosis of myocardial injury and types 1 and 2 myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 546-557.	0.4	6
15	Structural Cardiac Abnormalities in Patients with Atrial Fibrillation/Flutter and Myocardial Injury. American Journal of Medicine, 2022, 135, 1488-1496.e5.	0.6	4
16	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. European Heart Journal, 2021, 42, 323-334.	1.0	68
17	ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB. European Heart Journal, 2021, 42, 2260-2264.	1.0	23
18	Biomarker and Invasive Hemodynamic Assessment of Cardiac Damage Class in Aortic Stenosis. Structural Heart, 2021, 5, 208-217.	0.2	1

#	Article	IF	Citations
19	Adjusting the MI Codes Into the Framework of the Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 858-860.	1.2	3
20	Getting Cardiac Troponin Right: Appraisal of the 2020 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation by the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Clinical Applications of Cardiac Bio-Markers. Clinical Chemistry, 2021, 67, 730-735.	1.5	28
21	Cardiovascular biomarkers in patients with COVID-19. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 310-319.	0.4	44
22	Prediction of Death After Noncardiac Surgery: Potential Advantage of Using Highâ€Sensitivity Troponin T as a Continuous Variable. Journal of the American Heart Association, 2021, 10, e018008.	1.6	7
23	Return-to-Play Guidelines for Athletes After COVID-19 Infection. JAMA Cardiology, 2021, 6, 479.	3.0	5
24	Racial Disparities in the Utilization and Outcomes of Temporary Mechanical Circulatory Support for Acute Myocardial Infarction-Cardiogenic Shock. Journal of Clinical Medicine, 2021, 10, 1459.	1.0	11
25	High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19. Clinical Chemistry, 2021, 67, 1080-1089.	1.5	28
26	Ceramide Scores Predict Cardiovascular Risk in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1558-1569.	1.1	29
27	Using high sensitivity cardiac troponin values in patients with SARS-CoV-2 infection (COVID-19): The Padova experience. Clinical Biochemistry, 2021, 90, 8-14.	0.8	18
28	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2021, 42, 2630-2642.	1.0	69
29	Clinical Impact of High-Sensitivity Cardiac Troponin T Implementation in theÂCommunity. Journal of the American College of Cardiology, 2021, 77, 3160-3170.	1.2	33
30	Raising the Bar for Clinical Cardiac Troponin Research Studies and Implementation Science. Circulation, 2021, 143, 2225-2228.	1.6	2
31	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. Journal of Cardiac Failure, 2021, 27, 1456-1461.	0.7	1
32	Pre-analytical considerations in biomarker research: focus on cardiovascular disease. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1747-1760.	1.4	10
33	Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community. Biomarkers, 2021, 26, 639-646.	0.9	7
34	Analytical and Clinical Considerations in Implementing the Roche Elecsys Troponin T Gen 5 STAT Assay. American Journal of Clinical Pathology, 2021, 156, 1121-1129.	0.4	7
35	Influence of primary payer status on non-ST-segment elevation myocardial infarction: 18-year retrospective cohort national temporal trends, management and outcomes. Annals of Translational Medicine, 2021, 9, 1075-1075.	0.7	1
36	High-Sensitivity Troponin: Revealing the Ominous Implications of Myocardial Injury in Critical Illness*. Critical Care Medicine, 2021, 49, 1572-1575.	0.4	0

#	Article	IF	Citations
37	An enhanced ceramide-based approach for primary prevention of atherosclerotic events. European Heart Journal Open, 2021, 1, .	0.9	7
38	The Elevated High-Sensitivity Cardiac Troponin T Pilot. Mayo Clinic Proceedings, 2021, 96, 2366-2375.	1.4	5
39	Temporal Trends, Predictors, and Outcomes of Acute Ischemic Stroke in Acute Myocardial Infarction in the United States. Journal of the American Heart Association, 2021, 10, e017693.	1.6	19
40	Reply. Journal of the American College of Cardiology, 2021, 78, e149-e150.	1.2	0
41	Sex-Specific 99th Percentile URLs for Cardiac Troponin Assaysâ€"Their Time Has Come. Clinical Chemistry, 2021, 67, 197-200.	1.5	8
42	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 343-355.	0.4	9
43	Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort. Circulation, 2020, 141, 454-463.	1.6	77
44	Early vs. delayed in-hospital cardiac arrest complicating ST-elevation myocardial infarction receiving primary percutaneous coronary intervention. Resuscitation, 2020, 148, 242-250.	1.3	44
45	Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young. Circulation: Heart Failure, 2020, 13, e007154.	1.6	71
46	Atherosclerotic Cardiovascular Disease RiskÂStratification Based on Measurements of Troponin and Coronary Artery Calcium. Journal of the American College of Cardiology, 2020, 76, 357-370.	1.2	32
47	Epidemiological Trends in the Timing of In-Hospital Death in Acute Myocardial Infarction-Cardiogenic Shock in the United States. Journal of Clinical Medicine, 2020, 9, 2094.	1.0	15
48	Management and outcomes of uncomplicated ST-segment elevation myocardial infarction patients transferred after fibrinolytic therapy. International Journal of Cardiology, 2020, 321, 54-60.	0.8	5
49	Influence of Human Immunodeficiency Virus Infection on the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 331-339.	0.9	2
50	99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction. Clinical Chemistry, 2020, 66, 1167-1180.	1.5	22
51	Intracranial Hemorrhage Complicating Acute Myocardial Infarction: An 18-Year National Study of Temporal Trends, Predictors, and Outcomes. Journal of Clinical Medicine, 2020, 9, 2717.	1.0	7
52	Sex and Gender Disparities in the Management and Outcomes of Acute Myocardial Infarctionâ€"Cardiogenic Shock inÂOlder Adults. Mayo Clinic Proceedings, 2020, 95, 1916-1927.	1.4	36
53	Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction. Circulation, 2020, 142, 1532-1544.	1.6	31
54	Weekend Effect in the Management and Outcomes of Acute Myocardial Infarction in the United States, 2000-2016. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 362-372.	1.2	25

#	Article	IF	Citations
55	Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors. Clinica Chimica Acta, 2020, 511, 138-142.	0.5	25
56	The Universal Definition of Myocardial Infarction. Circulation, 2020, 141, 1434-1436.	1.6	26
57	Myocardial injury in severe COVID-19 infection. European Heart Journal, 2020, 41, 2080-2082.	1.0	38
58	Implementing High-Sensitivity Cardiac Troponin T in a US Regional Healthcare System. Circulation, 2020, 141, 1937-1939.	1.6	15
59	Complications in Patients with Acute Myocardial Infarction Supported with Extracorporeal Membrane Oxygenation. Journal of Clinical Medicine, 2020, 9, 839.	1.0	29
60	Our nearly complete diagnostic trip of thousands of steps begets a new trip therapeutically. European Heart Journal, 2020, 41, 2217-2219.	1.0	2
61	The Gloomy Long-Term Prognosis of Patients With Type 2 Myocardial Infarction orÂMyocardial Injury. Journal of the American College of Cardiology, 2020, 75, 1014-1016.	1.2	5
62	Cardiac Troponin for Assessment of Myocardial Injury in COVID-19. Journal of the American College of Cardiology, 2020, 76, 1244-1258.	1.2	322
63	Prognostic Value of N-Terminal Pro-form B-Type Natriuretic Peptide in Patients With Moderate Aortic Stenosis. American Journal of Cardiology, 2020, 125, 1566-1570.	0.7	20
64	Regional Variation in the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock in the United States. Circulation: Heart Failure, 2020, 13, e006661.	1.6	64
65	Natriuretic Peptides to Predict Short-Term Mortality in Patients With Sepsis: A Systematic Review and Meta-analysis. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 50-64.	1.2	30
66	Pulmonary artery catheter use in acute myocardial infarctionâ€cardiogenic shock. ESC Heart Failure, 2020, 7, 1234-1245.	1.4	54
67	Acute Myocardial Infarction Due to Fixed Coronary Artery Stenosis From Myocardial Bridging. Cardiovascular Revascularization Medicine, 2020, 21, 91-93.	0.3	4
68	ST-segment Elevation, Myocardial Injury, and Suspected or Confirmed COVID-19 Patients: Diagnostic and Treatment Uncertainties. Mayo Clinic Proceedings, 2020, 95, 1107-1111.	1.4	11
69	Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. Clinical Biochemistry, 2020, 86, 45-51.	0.8	14
70	Influence of primary payer status on the management and outcomes of ST-segment elevation myocardial infarction in the United States. PLoS ONE, 2020, 15, e0243810.	1.1	6
71	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	1.0	2,687
72	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Clinical Chemistry, 2019, 65, 1221-1227.	1.5	21

#	Article	IF	Citations
73	Should myocardial infarction type 2 be regarded as two separate entities?. European Heart Journal, 2019, 40, 2810-2812.	1.0	4
74	Changes in comorbidities, diagnoses, therapies and outcomes in a contemporary cardiac intensive care unit population. American Heart Journal, 2019, 215, 12-19.	1.2	87
75	Sex disparities in acute kidney injury complicating acute myocardial infarction with cardiogenic shock. ESC Heart Failure, 2019, 6, 874-877.	1.4	53
76	Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000â€“2014. Annals of Intensive Care, 2019, 9, 96.	2.2	71
77	Estimating short- and long-term reference change values and index of individuality for tests of platelet function. Clinical Biochemistry, 2019, 74, 54-59.	0.8	2
78	It Will Take More Than Better DiagnosticsÂto Improve the Care of Women With ACS. Journal of the American College of Cardiology, 2019, 74, 2044-2046.	1.2	4
79	Temporal trends, predictors, and outcomes of acute kidney injury and hemodialysis use in acute myocardial infarction-related cardiogenic shock. PLoS ONE, 2019, 14, e0222894.	1.1	51
80	78-Year-Old Woman With Intermittent Chest Pain and Palpitations. Mayo Clinic Proceedings, 2019, 94, e117-e121.	1.4	0
81	Letter by Sandoval et al Regarding Article, â€œDesigning a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation â€œHigh-Sensitivityâ€• Cardiac Troponin Assays to Diagnose Myocardial Infarctionâ€• Circulation, 2019, 139, 562-563.	1.6	3
82	Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas Ã cause du BNP?. European Journal of Heart Failure, 2019, 21, 609-612.	2.9	3
83	Temporal trends and outcomes of prolonged invasive mechanical ventilation and tracheostomy use in acute myocardial infarction with cardiogenic shock in the United States. International Journal of Cardiology, 2019, 285, 6-10.	0.8	60
84	Acute Noncardiac Organ Failure in AcuteÂMyocardial Infarction With Cardiogenic Shock. Journal of the American College of Cardiology, 2019, 73, 1781-1791.	1.2	156
85	Type 2 Myocardial Infarction. Journal of the American College of Cardiology, 2019, 73, 1846-1860.	1.2	199
86	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. Journal of the American College of Cardiology, 2019, 73, 1059-1077.	1.2	103
87	Extracorporeal Membrane Oxygenation Use in Acute Myocardial Infarction in the United States, 2000 to 2014. Circulation: Heart Failure, 2019, 12, e005929.	1.6	91
88	Global Adoption of High-Sensitivity Cardiac Troponins and the Universal Definition of Myocardial Infarction. Clinical Chemistry, 2019, 65, 484-489.	1.5	76
89	High-Sensitivity Cardiac Troponin I Levels in Normal and Hypertensive Pregnancy. American Journal of Medicine, 2019, 132, 362-366.	0.6	28
90	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). Clinical Chemistry and Laboratory Medicine, 2019, 57, 633-640.	1.4	33

#	Article	IF	Citations
91	Clinical use of cardiac troponin for acute cardiac care and emerging opportunities in the outpatient setting. Minerva Medica, 2019, 110, 139-156.	0.3	5
92	Fourth Universal Definition of Myocardial Infarction: Will it change how we practice emergency medicine?. Emergencias, 2019, 31, 55-57.	0.6	2
93	The prognostic impact of periprocedural myocardial infarction and injury. European Heart Journal, 2018, 39, 1110-1112.	1.0	22
94	Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry, 2018, 64, 645-655.	1.5	327
95	Reply to letter by Trupp et al.. Clinical Biochemistry, 2018, 52, 174.	0.8	1
96	Meta-Analyses and Interpretation of Troponin Values in Heart Failure. JACC: Heart Failure, 2018, 6, 198-200.	1.9	2
97	Comparing analytical outliers and the percent of emergency department patients with results above the 99th percentile upper reference limit for 2 conventional and one high sensitivity troponin assay. Clinical Biochemistry, 2018, 53, 104-109.	0.8	8
98	Science Moves Slowly. Journal of the American College of Cardiology, 2018, 71, 1550-1552.	1.2	8
99	Clarifying the Proper Definitions for Type 2 Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 1291.	1.2	4
100	What to do when you question cardiac troponin values. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 577-586.	0.4	66
101	Improving the Specificity of Cardiac Biomarkersâ€"The Early Development of Cardiac Troponin I (cTnI) Assays. Clinical Chemistry, 2018, 64, 609-610.	1.5	0
102	ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome). Circulation, 2018, 137, 354-363.	1.6	32
103	Analytical performance of an immunoassay to measure proenkephalin. Clinical Biochemistry, 2018, 58, 72-77.	0.8	28
104	Detectable High-Sensitivity Cardiac Troponin within the Population Reference Interval Conveys High 5-Year Cardiovascular Risk: An Observational Study. Clinical Chemistry, 2018, 64, 1044-1053.	1.5	33
105	1-h High-Sensitivity Troponin Rule-Out and Rule-In Approach. Journal of the American College of Cardiology, 2018, 72, 633-635.	1.2	6
106	Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. Clinical Biochemistry, 2018, 60, 11-16.	0.8	60
107	Possible mechanisms behind cardiac troponin elevations. Biomarkers, 2018, 23, 725-734.	0.9	95
108	Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery. American Heart Journal, 2018, 203, 67-73.	1.2	31

#	Article	IF	Citations
109	Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology, 2018, 72, 2231-2264.	1.2	2,285
110	Fourth Universal Definition of Myocardial Infarction (2018). Circulation, 2018, 138, e618-e651.	1.6	1,858
111	Fourth Universal Definition of Myocardial Infarction (2018). , 2018, 13, 305-338.		237
112	Use of High-Sensitivity Cardiac Troponin in Patients With Chronic Comorbidities. Journal of the American College of Cardiology, 2018, 72, 1138-1140.	1.2	5
113	Plasma Ceramides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1933-1939.	1.1	147
114	High-Sensitivity Troponin in Patients With Coronary Artery Endothelial Dysfunction. Journal of Invasive Cardiology, 2018, 30, 406-410.	0.4	6
115	Editorâ€™s Choice-Rule-in of acute myocardial infarction: Focus on troponin. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 212-217.	0.4	32
116	Does cardiac rhythm monitoring in patients with elevated troponin levels lead to changes in management?. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 545-552.	0.4	2
117	Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 218-222.	0.4	70
118	Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. Anesthesia and Analgesia, 2017, 124, 398-405.	1.1	51
119	Effect of Repeat Measurements of High-Sensitivity Cardiac Troponin on the Same Sample Using the European Society of Cardiology 0-Hour/1-Hour or 2-Hour Algorithms for Early Rule-Out and Rule-In for Myocardial Infarction. Clinical Chemistry, 2017, 63, 1163-1165.	1.5	25
120	Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes. Current Cardiology Reports, 2017, 19, 48.	1.3	13
121	Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. JAMA - Journal of the American Medical Association, 2017, 317, 1642.	3.8	579
122	Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection. Annals of Internal Medicine, 2017, 166, 715.	2.0	231
123	In Reply. Clinical Chemistry, 2017, 63, 1167-1170.	1.5	7
124	Using Biomarkers to Guide Heart Failure Therapy. Clinical Chemistry, 2017, 63, 954-957.	1.5	6
125	Biological variability of lipoprotein-associated phospholipase A 2 activity in healthy individuals. Clinical Biochemistry, 2017, 50, 347-349.	0.8	4
126	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. American Heart Journal, 2017, 190, 135-139.	1.2	26

#	Article	IF	Citations
127	Another Unanswerable Question. JACC Basic To Translational Science, 2017, 2, 115-117.	1.9	5
128	Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. American Journal of Medicine, 2017, 130, 1112.e9-1112.e15.	0.6	61
129	Natriuretic Peptides and Analytical Barriers. Clinical Chemistry, 2017, 63, 50-58.	1.5	34
130	Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care. Clinical Chemistry, 2017, 63, 73-81.	1.5	277
131	Best Practices for Monitoring Cardiac Troponin in Detecting Myocardial Injury. Clinical Chemistry, 2017, 63, 37-44.	1.5	9
132	Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides. Clinical Chemistry, 2017, 63, 351-358.	1.5	58
133	Commentary. Clinical Chemistry, 2017, 63, 48-49.	1.5	0
134	Using High-Sensitivity Cardiac Troponin T for Acute Cardiac Care. American Journal of Medicine, 2017, 130, 1358-1365.e1.	0.6	47
135	High-Sensitivity Cardiac Troponin for the Diagnosis of Patients with Acute Coronary Syndromes. Current Cardiology Reports, 2017, 19, 92.	1.3	37
136	Renal Dysfunction: How to Think About That in Acute Coronary Syndromes. Current Cardiology Reports, 2017, 19, 91.	1.3	1
137	Sex-specific 99th percentiles derived from the AACC Universal Sample Bank for the Roche Gen 5 cTnT assay: Comorbidities and statistical methods influence derivation of reference limits. Clinical Biochemistry, 2017, 50, 1073-1077.	0.8	29
138	High-Sensitivity Cardiac Troponin T Improves the Diagnosis of Perioperative MI. Anesthesia and Analgesia, 2017, 125, 1455-1462.	1.1	21
139	Eliminating Creatine Kinaseâ€“Myocardial Band Testing in Suspected Acute Coronary Syndrome. JAMA Internal Medicine, 2017, 177, 1508.	2.6	46
140	Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicityâ€². Journal of the American Heart Association, 2017, 6, .	1.6	18
141	Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70Âmg/dL compared with a novel low-density lipoprotein estimation method. Journal of Clinical Lipidology, 2017, 11, 1065-1072.	0.6	37
142	High-Sensitivity Cardiac Troponin andÂPrimary Prevention. Journal of the American College of Cardiology, 2016, 68, 2729-2732.	1.2	7
143	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally?Sometimes earlier may not be betterBackground, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. European Heart Journal, 2016, 37, 3316-3323.	1.0	26
144	How Good Does It Need to Be? â^—. Journal of the American College of Cardiology, 2016, 67, 1541-1543.	1.2	0

#	Article	IF	Citations
145	From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. Journal of Heart and Lung Transplantation, 2016, 35, 714-721.	0.3	15
146	Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients. Clinical Chemistry, 2016, 62, 824-830.	1.5	21
147	Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within Practice. Annals of Emergency Medicine, 2016, 68, 93-102.e1.	0.3	107
148	Biomarkers in heart failure: the importance of inconvenient details. ESC Heart Failure, 2016, 3, 3-10.	1.4	21
149	Ruling-In Myocardial Injury and Ruling-Out Myocardial Infarction With the European Society of Cardiology 1-Hour Algorithm. Circulation, 2016, 134, 1542-1545.	1.6	29
150	Biomarkerâ€based risk prediction in the community. European Journal of Heart Failure, 2016, 18, 1342-1350.	2.9	27
151	High-Sensitivity Troponin in the Triage ofÂAcute Decompensated Heart Failure â^—. JACC: Heart Failure, 2016, 4, 600-602.	1.9	2
152	TRAPID or Trapped?. Annals of Emergency Medicine, 2016, 68, 88-91.	0.3	18
153	Elevation of cardiac troponin T in patients with amyotrophic lateral sclerosis. Acta Neurologica Belgica, 2016, 116, 557-564.	0.5	8
154	Advantages of the lipoprotein-associated phospholipase A2 activity assay. Clinical Biochemistry, 2016, 49, 172-175.	0.8	25
155	Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2016, 22, 249-255.	0.7	31
156	Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromesâ€"The COPACS Study. American Journal of Medicine, 2016, 129, 105-114.	0.6	8
157	Can Natriuretic Peptides be Used to Guide Therapy?. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2016, 27, 208-16.	0.7	9
158	High Sensitivity Cardiac Troponin Assays - How to Implement them Successfully. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2016, 27, 217-23.	0.7	6
159	Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the <scp>CHOPIN</scp> Trial. Academic Emergency Medicine, 2015, 22, 554-563.	0.8	10
160	Can amyotrophic lateral sclerosis chronically elevate troponin T?. Cor Et Vasa, 2015, 57, e320-e322.	0.1	3
161	Biochemical Validation of Patient-Reported Symptom Onset Time in PatientsÂWith ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2015, 8, 778-787.	1.1	11
162	High-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective Evaluation. Clinical Chemistry, 2015, 61, 983-989.	1.5	97

#	Article	IF	Citations
163	Troponin T as a Predictor of End-Stage Renal Disease and All-Cause Death in African Americans and Whites From Hypertensive Families. Mayo Clinic Proceedings, 2015, 90, 1482-1491.	1.4	7
164	Myocardial Dysfunction in Severe Sepsis and Septic Shock. Chest, 2015, 148, 93-102.	0.4	71
165	Unwinding the Interaction of Natriuretic Peptides andÂNeprilysinâˆ—. Journal of the American College of Cardiology, 2015, 65, 666-667.	1.2	10
166	Better Ways to Move Ahead. Journal of Cardiac Failure, 2015, 21, 362-363.	0.7	0
167	Vasospasm and Type 2 AMI?. American Journal of Medicine, 2015, 128, 329-330.	0.6	1
168	Sensitive Troponin Assay and the Classification of Myocardial Infarction. American Journal of Medicine, 2015, 128, 493-501.e3.	0.6	134
169	Soluble ST2â€"Analytical Considerations. American Journal of Cardiology, 2015, 115, 8B-21B.	0.7	86
170	Acute Coronary Syndromes in the Community. Mayo Clinic Proceedings, 2015, 90, 597-605.	1.4	13
171	Release of cardiac troponin using a high sensitivity assay after exercise: Type 2 acute myocardial infarction?. Clinica Chimica Acta, 2015, 446, 6-8.	0.5	7
172	Reliability of Calculated Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2015, 116, 538-540.	0.7	33
173	Unraveling N-Terminal Proâ€"B-Type Natriuretic Peptide: Another Piece to a Very Complex Puzzle in Heart Failure Patients. Clinical Chemistry, 2015, 61, 1016-1018.	1.5	23
174	Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clinical Biochemistry, 2015, 48, 1337-1340.	0.8	45
175	MY APPROACH to cardiac troponin elevations in patients with renal disease. Trends in Cardiovascular Medicine, 2015, 25, 655-656.	2.3	0
176	Sex-Specific Associations of Established and Emerging Cardiac Biomarkers with All-Cause Mortality in Older Adults: The ActiFE Study. Clinical Chemistry, 2015, 61, 389-399.	1.5	35
177	Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis. American Heart Journal, 2015, 169, 6-16.e6.	1.2	89
178	IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clinical Biochemistry, 2015, 48, 201-203.	0.8	224
179	Fundamental Concepts of Effective Troponin Use: Important Principles for Internists. American Journal of Medicine, 2015, 128, 111-119.	0.6	17
180	Intervention to Reduce Inappropriate Ionized Calcium Ordering Practices: A Quality-Improvement Project. , 2015, 19, 49-51.		13

#	Article	IF	Citations
181	Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin. Clinical Biochemistry, 2014, 47, 155-157.	0.8	7
182	High-sensitivity troponin: where are we now and where do we go from here?. Biomarkers in Medicine, 2014, 8, 1021-1032.	0.6	6
183	Validation of a Proposed Novel Equation for Estimating LDL Cholesterol. Clinical Chemistry, 2014, 60, 1519-1523.	1.5	62
184	2014 AHA/ACC Guideline for the Management of Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes. Circulation, 2014, 130, e344-426.	1.6	928
185	Defining the Optimal Cardiac Troponin T Threshold for Predicting Death Caused by Periprocedural Myocardial Infarction After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 533-542.	1.4	14
186	Troponin Elevation in Severe Sepsis and Septic Shock. Critical Care Medicine, 2014, 42, 790-800.	0.4	182
187	B-Type Natriuretic Peptide Clinical Activation in Aortic Stenosis. Journal of the American College of Cardiology, 2014, 63, 2016-2025.	1.2	172
188	Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease. Clinical Biochemistry, 2014, 47, 177-183.	0.8	12
189	Prognostic performance of high-sensitivity cardiac troponin T kinetic changes adjusted for elevated admission values and the GRACE score in an unselected emergency department population. Clinica Chimica Acta, 2014, 435, 29-35.	0.5	4
190	Clinical implications of the Third Universal Definition of Myocardial Infarction. Heart, 2014, 100, 424-432.	1.2	46
191	Republished: Clinical implications of the Third Universal Definition of Myocardial Infarction. Postgraduate Medical Journal, 2014, 90, 502-510.	0.9	4
192	Improving the 510(k) FDA Process for Cardiac Troponin Assays: In Search of Common Ground. Clinical Chemistry, 2014, 60, 1273-1275.	1.5	17
193	High-Sensitivity Cardiac Troponin Assays: Isn't It Time for Equality?. Clinical Chemistry, 2014, 60, 7-9.	1.5	22
194	Men are different than women: It's true for cardiac troponin too. Clinical Biochemistry, 2014, 47, 867-868.	0.8	18
195	Natriuretic Peptides in Heart Failure. Clinical Chemistry, 2014, 60, 1040-1046.	1.5	21
196	2014 AHA/ACC Guideline for theÂManagement of Patients WithÂNonâ€“ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 64, e139-e228.	1.2	2,746
197	High-Sensitivity Troponin I and Amino-Terminal Proâ€“B-Type Natriuretic Peptide Predict Heart Failure and Mortality in the General Population. Clinical Chemistry, 2014, 60, 1225-1233.	1.5	49
198	In search for the Holy Grail: Suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 313-316.	0.4	30

#	Article	IF	Citations
199	Early Trends in N-Terminal Proâ€“Brain Natriuretic Peptide Values After Left Ventricular Assist Device Implantation for Chronic Heart Failure. American Journal of Cardiology, 2014, 114, 1257-1263.	0.7	10
200	Nocturnal patterns of heart rate and the risk of mortality after acute myocardial infarction. American Heart Journal, 2014, 168, 117-125.	1.2	14
201	Copeptin Helps in the Early Detection of Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 150-160.	1.2	153
202	Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. Clinical Biochemistry, 2013, 46, 1636-1643.	0.8	100
203	Preparing the United States for High-Sensitivity Cardiac Troponin Assays. Journal of the American College of Cardiology, 2013, 61, 1753-1758.	1.2	129
204	Troponina cardiaca ultrasensible: de la teorÃa a la prÃ¡ctica clÃnica. Revista Espanola De Cardiologia, 2013, 66, 687-691.	0.6	31
205	Long-time quality assessment of the Elecsys Troponin T hs assay. Clinical Biochemistry, 2013, 46, 1055-1057.	0.8	32
206	High-sensitivity Cardiac Troponin: From Theory to Clinical Practice. Revista Espanola De Cardiologia (English Ed), 2013, 66, 687-691.	0.4	23
207	Another Piece to the TroponinÂPuzzle. Journal of the American College of Cardiology, 2013, 62, 641-642.	1.2	3
208	Third Universal Definition of Myocardial Infarction. Clinical Biochemistry, 2013, 46, 1-4.	0.8	48
209	Documento de consenso de expertos. Tercera definiciÃ³n universal del infarto de miocardio. Revista Espanola De Cardiologia, 2013, 66, 132.e1-132.e15.	0.6	18
210	Reply. Journal of the American College of Cardiology, 2013, 62, 648.	1.2	0
211	Elevated Cardiac Troponin T Levels in Critically Ill Patients with Sepsis. American Journal of Medicine, 2013, 126, 1114-1121.	0.6	67
212	Using High-sensitivity Troponin T: The Importance of the Proper Gold Standard. American Journal of Medicine, 2013, 126, 709-717.	0.6	54
213	High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. American Heart Journal, 2013, 166, 325-332.e1.	1.2	142
214	Short- and Long-term Individual Variation in Cardiac Troponin in Patients with Stable Coronary Artery Disease. Clinical Chemistry, 2013, 59, 401-409.	1.5	66
215	Defining High-Sensitivity Cardiac Troponin Concentrations in the Community. Clinical Chemistry, 2013, 59, 1099-1107.	1.5	118
216	Ninety-Minute vs 3-h Performance of High-Sensitivity Cardiac Troponin Assays for Predicting Hospitalization for Acute Coronary Syndrome. Clinical Chemistry, 2013, 59, 1407-1410.	1.5	22

#	Article	IF	Citations
217	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
218	Interpreting Biomarkers During Percutaneous Coronary Intervention: The Need to Reevaluate Our Approach. Archives of Internal Medicine, 2012, 172, 508.	4.3	3
219	Incidence and significance of elevated lactate in the identification of critically ill patients. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1819-23.	1.4	1
220	Why all the struggle about CK-MB and PCI?. European Heart Journal, 2012, 33, 1046-1048.	1.0	36
221	Decision Support Tool for Early Differential Diagnosis of Acute Lung Injury and Cardiogenic Pulmonary Edema in Medical Critically Ill Patients. Chest, 2012, 141, 43-50.	0.4	20
222	Troponin Releaseâ€"Reversible or Irreversible Injury? Should We Care?. Clinical Chemistry, 2012, 58, 148-150.	1.5	56
223	Prognostic Value of Cardiac Troponin T After Myocardial Infarction: A Contemporary Community Experience. Mayo Clinic Proceedings, 2012, 87, 247-254.	1.4	28
224	Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. European Heart Journal, 2012, 33, 2001-2006.	1.0	233
225	Diastolic dysfunction and mortality in severe sepsis and septic shock. European Heart Journal, 2012, 33, 895-903.	1.0	352
226	Third universal definition of myocardial infarction. Nature Reviews Cardiology, 2012, 9, 620-633.	6.1	2,615
227	How to use high-sensitivity cardiac troponins in acute cardiac care. European Heart Journal, 2012, 33, 2252-2257.	1.0	666
228	Evaluation of Patients With Possible Cardiac Chest Pain. Journal of the American College of Cardiology, 2012, 59, 2099-2100.	1.2	9
229	Troponinâ€"Past, Present, and Future. Current Problems in Cardiology, 2012, 37, 209-228.	1.1	33
230	Third Universal Definition of Myocardial Infarction. Global Heart, 2012, 7, 275.	0.9	309
231	Cardiac Function. , 2012, , 1457-1522.		2
232	Rapid Exclusion of Acute Myocardial Infarction in Patients With Undetectable Troponin Using a High-Sensitivity Assay. Journal of the American College of Cardiology, 2011, 58, 1332-1339.	1.2	325
233	Diseased Skeletal Muscle. Journal of the American College of Cardiology, 2011, 58, 1819-1824.	1.2	244
234	Troponin Elevations After Electroconvulsive Therapy: The Need for Caution. American Journal of Medicine, 2011, 124, 229-234.	0.6	13

#	Article	IF	Citations
235	Clinical implications of the change of cardiac troponin I levels in patients with acute chest pain â€" An evaluation with respect to the Universal Definition of Myocardial Infarction. Clinica Chimica Acta, 2011, 412, 91-97.	0.5	44
236	The 10 commandments of troponin, with special reference to high sensitivity assays. Heart, 2011, 97, 940-946.	1.2	54
237	The clinical impact of circulating caspase-3 p17 level: a potential new biomarker for myocardial injury and cardiovascular disease. Future Cardiology, 2011, 7, 443-445.	0.5	5
238	Comparison of Mass Spectrometry and Clinical Assay Measurements of Circulating Fragments of B-Type Natriuretic Peptide in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2011, 4, 355-360.	1.6	108
239	Biologic Variation of a Novel Cardiac Troponin I Assay. Clinical Chemistry, 2011, 57, 1080-1081.	1.5	32
240	Biomarkers in Acute Ischemic Heart Disease. , 2011, , 101-112.		1
241	Biochemical markers of myocardial necrosis. , 2011, , 125-131.		0
242	Identification of myocardial injury in the emergency setting. Clinical Biochemistry, 2010, 43, 539-544.	0.8	11
243	Determinants and prognostic implications of Cardiac Troponin T measured by a sensitive assay in Type 2 Diabetes Mellitus. Cardiovascular Diabetology, 2010, 9, 52.	2.7	36
244	Biological and Analytical Variability of a Novel High-Sensitivity Cardiac Troponin T Assay. Clinical Chemistry, 2010, 56, 1086-1090.	1.5	140
245	Analytical Validation of a High-Sensitivity Cardiac Troponin T Assay. Clinical Chemistry, 2010, 56, 254-261.	1.5	926
246	Being Rational about (Im)precision: A Statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the Definition of Myocardial Infarction. Clinical Chemistry, 2010, 56, 941-943.	1.5	120
247	High-Sensitivity Cardiac Troponin: Hype, Help, and Reality. Clinical Chemistry, 2010, 56, 342-344.	1.5	35
248	Increasing Cardiac Troponin Changes Measured by a Research High-Sensitivity Troponin I Assay: Absolute vs Percentage Changes and Long-Term Outcomes in a Chest Pain Cohort. Clinical Chemistry, 2010, 56, 1902-1904.	1.5	36
249	High Sensitivity Troponin in Chest Pain and Acute Coronary Syndromes. A Step Forward?. Revista Espanola De Cardiologia (English Ed), 2010, 63, 763-769.	0.4	13
250	High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease: An initial foray. Clinica Chimica Acta, 2010, 411, 812-817.	0.5	19
251	Significance of Elevated Cardiac Troponin T Levels in Critically Ill Patients with Acute Respiratory Disease. American Journal of Medicine, 2010, 123, 1049-1058.	0.6	49
252	Recommendations for the use of cardiac troponin measurement in acute cardiac care. European Heart Journal, 2010, 31, 2197-2204.	1.0	533

#	Article	IF	Citations
253	Value of Cardiac Troponin I Cutoff Concentrations below the 99th Percentile for Clinical Decision-Making. Clinical Chemistry, 2009, 55, 85-92.	1.5	127
254	Perioperative Myocardial Infarction. Circulation, 2009, 119, 2936-2944.	1.6	396
255	Refining Our Criteria. American Journal of Clinical Pathology, 2009, 131, 11-13.	0.4	5
256	Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. Nephrology Dialysis Transplantation, 2009, 24, 2452-2457.	0.4	22
257	Short- and Long-Term Risk Stratification Using a Next-Generation, High-Sensitivity Research Cardiac Troponin I (hs-cTnI) Assay in an Emergency Department Chest Pain Population. Clinical Chemistry, 2009, 55, 1809-1815.	1.5	88
258	PAPP-A as a marker of increased long-term risk in patients with chest pain. Clinical Biochemistry, 2009, 42, 1012-1018.	0.8	26
259	Aborted myocardial infarction: Is it real in the troponin era?. American Heart Journal, 2009, 157, 636-641.	1.2	9
260	Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial Injury. Clinical Chemistry, 2009, 55, 573-577.	1.5	165
261	History of Depression and Survival After Acute Myocardial Infarction. Psychosomatic Medicine, 2009, 71, 253-259.	1.3	66
262	Long-term prognostic significance of elevated cardiac troponin levels in critically ill patients with acute gastrointestinal bleeding*. Critical Care Medicine, 2009, 37, 140-147.	0.4	62
263	Depression and five year survival following acute myocardial infarction: A prospective study. Journal of Affective Disorders, 2008, 109, 133-138.	2.0	79
264	Cardiac Magnetic Resonance Imaging Study for Quantification of Infarct Size Comparing Directly Serial Versus Single Time-Point Measurements of Cardiac Troponin T. Journal of the American College of Cardiology, 2008, 51, 307-314.	1.2	162
265	Weight Change after Myocardial Infarctionâ€"the Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) Experience. American Heart Journal, 2008, 155, 478-484.	1.2	50
266	The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. American Heart Journal, 2008, 155, 208-214.	1.2	137
267	â€œUpstream markersâ€•provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. Clinica Chimica Acta, 2008, 387, 133-138.	0.5	13
268	Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clinica Chimica Acta, 2008, 393, 103-109.	0.5	42
269	Requiem for a Heavyweight. Circulation, 2008, 118, 2200-2206.	1.6	104
270	Significance of Periprocedural Myonecrosis on Outcomes After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2008, 1, 10-19.	1.4	165

#	Article	IF	Citations
271	Cross-Reactivity of BNP, NT-proBNP, and proBNP in Commercial BNP and NT-proBNP Assays: Preliminary Observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clinical Chemistry, 2008, 54, 619-621.	1.5	124
272	Implications of the universal definition of myocardial infarction. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 678-679.	3.3	13
273	Relationship of MRI-Determined Infarct Size and cTnI Measurements in Patients with ST-Elevation Myocardial Infarction. Clinical Chemistry, 2008, 54, 617-619.	1.5	42
274	Key Issues in the Developing Synergism between Cardiovascular Imaging and Biomarkers. Clinical Chemistry, 2008, 54, 1432-1442.	1.5	12
275	The clinical impact of the universal diagnosis of myocardial infarction. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1485-8.	1.4	6
276	Diagnostic accuracy of clinical prediction rules to exclude acute coronary syndrome in the emergency department setting: a systematic review. Canadian Journal of Emergency Medicine, 2008, 10, 373-382.	0.5	62
277	Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Critical Care Medicine, 2008, 36, 759-765.	0.4	131
278	Nighttime Heart Rate and Survival in Depressed Patients Post Acute Myocardial Infarction. Psychosomatic Medicine, 2008, 70, 757-763.	1.3	10
279	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. Clinical Chemistry, 2007, 53, 2086-2096.	1.5	239
280	Myocardial Infarction with Normal Coronary Arteries: A Role for MRI?. Clinical Chemistry, 2007, 53, 995-996.	1.5	22
281	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. Clinical Chemistry, 2007, 53, 547-551.	1.5	188
282	Regional Systems of Care to Optimize Timeliness of Reperfusion Therapy for ST-Elevation Myocardial Infarction. Circulation, 2007, 116, 729-736.	1.6	299
283	B-type natriuretic peptides in heart failure: update on clinical applications and limitations. Biomarkers in Medicine, 2007, 1, 503-512.	0.6	2
284	Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure. Circulation, 2007, 116, 249-257.	1.6	161
285	Universal Definition of Myocardial Infarction. Circulation, 2007, 116, 2634-2653.	1.6	2,755
286	Long-Term Health Outcomes Associated with Detectable Troponin I Concentrations. Clinical Chemistry, 2007, 53, 220-227.	1.5	67
287	Social support and prognosis in patients at increased psychosocial risk recovering from myocardial infarction.. Health Psychology, 2007, 26, 418-427.	1.3	112
288	Heart Rate Turbulence, Depression, and Survival After Acute Myocardial Infarction. Psychosomatic Medicine, 2007, 69, 4-9.	1.3	43

#	Article	IF	Citations
289	Cardiovascular biomarkers: The state of the art in 2006. Clinica Chimica Acta, 2007, 381, 9-13.	0.5	20
290	Multi-center validation of the Response Biomedical Corporation RAMPÂ® NT-proBNP assay with comparison to the Roche Diagnostics GmbH ElecsysÂ® proBNP assay. Clinica Chimica Acta, 2007, 386, 20-24.	0.5	23
291	The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes. Medical Clinics of North America, 2007, 91, 657-681.	1.1	22
292	Usefulness of Detectable Levels of Troponin, Below the 99th Percentile of the Normal Range, as a Clue to the Presence of Underlying Coronary Artery Disease. American Journal of Cardiology, 2007, 100, 764-769.	0.7	50
293	Assessing the Requirement for the 6-Hour Interval between Specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clinical Chemistry, 2006, 52, 812-818.	1.5	179
294	Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. European Heart Journal, 2006, 27, 1061-1069.	1.0	129
295	Brain Natriuretic Peptide Levels in Constrictive Pericarditis and Restrictive Cardiomyopathy. Journal of the American College of Cardiology, 2006, 47, 1489-1491.	1.2	56
296	Biomarkers in Acute Cardiac Disease. Journal of the American College of Cardiology, 2006, 48, 1-11.	1.2	1,289
297	Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study. American Heart Journal, 2006, 152, 126-135.	1.2	66
298	Lipoproteinâ€Associated Phospholipase A 2 : Review and Recommendation of a Clinical Cut Point for Adults. Preventive Cardiology, 2006, 9, 138-143.	1.1	44
299	Elevations of troponin in patients with epileptic seizures? What do they mean?. Clinical Cardiology, 2006, 29, 325-326.	0.7	15
300	Lipoprotein-Associated Phospholipase A2and Prognosis After Myocardial Infarction in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2517-2522.	1.1	85
301	Redefinition of Myocardial Infarction. Circulation, 2006, 114, 790-797.	1.6	133
302	Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected Cohort of Troponin-Naiˆve Emergency Department Patients. Clinical Chemistry, 2006, 52, 2028-2035.	1.5	24
303	Importance of Low Concentrations of Cardiac Troponins. Clinical Chemistry, 2006, 52, 1614-1615.	1.5	35
304	Lower Rather Than Higher Levels of B-Type Natriuretic Peptides (NTâ€“Pro-BNP and BNP) Predict Short-Term Mortality in End-Stage Heart Failure Patients Treated With Nesiritide. American Journal of Cardiology, 2005, 96, 837-841.	0.7	41
305	Effects of Antidepressant Medication on Morbidity and Mortality in Depressed Patients After Myocardial Infarction. Archives of General Psychiatry, 2005, 62, 792.	13.8	469
306	Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clinical Chemistry, 2005, 51, 810-824.	1.5	385

#	Article	IF	Citations
307	Quality Specifications for B-Type Natriuretic Peptide Assays. Clinical Chemistry, 2005, 51, 486-493.	1.5	181
308	Troponin: the biomarker of choice for the detection of cardiac injury. Cmaj, 2005, 173, 1191-1202.	0.9	509
309	Practical Implementation of the Guidelines for Unstable Angina/Nonâ€“ST-Segment Elevation Myocardial Infarction in the Emergency Department. Circulation, 2005, 111, 2699-2710.	1.6	109
310	Can creatine kinase MB levels predict mortality after cardiac surgery?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 280-281.	3.3	1
311	Biomarker Responses during and after Treatment with Nesiritide Infusion in Patients with Decompensated Chronic Heart Failure. Clinical Chemistry, 2005, 51, 569-577.	1.5	47
312	Use of Biomarkers in the Emergency Department and Chest Pain Unit. Cardiology Clinics, 2005, 23, 453-465.	0.9	16
313	Validation of the 99th Percentile Cutoff Independent of Assay Imprecision (CV) for Cardiac Troponin Monitoring for Ruling Out Myocardial Infarction. Clinical Chemistry, 2005, 51, 2198-2200.	1.5	123
314	Acute Coronary Syndrome Biomarkers. Circulation, 2004, 110, 104-106.	1.6	50
315	Clinical characteristics and Thrombolysis In Myocardial Infarction frame counts in women with transient left ventricular apical ballooning syndrome. American Journal of Cardiology, 2004, 94, 343-346.	0.7	546
316	Timing of Peak Troponin T and Creatine Kinase-MB Elevations After Percutaneous Coronary Intervention. Chest, 2004, 125, 275-280.	0.4	50
317	Case Definitions for Acute Coronary Heart Disease in Epidemiology and Clinical Research Studies. Circulation, 2003, 108, 2543-2549.	1.6	719
318	Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination. Annals of Internal Medicine, 2002, 137, 563.	2.0	522
319	European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials. American Heart Journal, 2002, 144, 981-986.	1.2	376
320	Effect of myocardial ischemia on cardiac troponin I and T. American Journal of Cardiology, 2002, 89, 224-226.	0.7	24
321	Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patients. American Journal of Cardiology, 2002, 90, 634-636.	0.7	59
322	Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels. American Journal of Cardiology, 2002, 90, 875-878.	0.7	26
323	Bedside Multimarker Testing for Risk Stratification in Chest Pain Units: The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) Study. Circulation, 2001, 104, .	1.6	8
324	Elevations in Cardiac Troponin Measurements: False False-Positives: The Real Truth. Cardiovascular Toxicology, 2001, 1, 087-092.	1.1	69

#	Article	IF	Citations
325	Cardiac Involvement in Patients With Acute Neurologic Disease. Archives of Internal Medicine, 2000, 160, 3153.	4.3	70
326	The Costs of Inadequate Data. Academic Emergency Medicine, 2000, 7, 687-688.	0.8	0
327	Itâ€™s Time for a Change to a Troponin Standard. Circulation, 2000, 102, 1216-1220.	1.6	584
328	Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. American Heart Journal, 2000, 140, 917-927.	1.2	232
329	Prognostic Influence of Elevated Values of Cardiac Troponin I in Patients With Unstable Angina. Circulation, 1997, 95, 2053-2059.	1.6	277
330	Diagnosis of Perioperative Myocardial Infarction with Measurement of Cardiac Troponin I. New England Journal of Medicine, 1994, 330, 670-674.	13.9	535
331	Recommended guidelines for in-hospital cardiac monitoring of adults for detection of arrhythmia. Journal of the American College of Cardiology, 1991, 18, 1431-1433.	1.2	71
332	Major depressive disorder in coronary artery disease. American Journal of Cardiology, 1987, 60, 1273-1275.	0.7	337
333	Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol. Frontiers in Genetics, 0, 13, .	1.1	6